Mayflower Bioscience

Executive Summary

Mayflower Bioscience is a Boston-based private biotechnology company founded in 2016 that provides innovative tools and reagents for drug discovery, cell biology, and molecular biology. The company's mission is to support researchers with high-quality products and services to accelerate breakthroughs in oncology and biologics. While Mayflower operates in a competitive market with established players, its focus on sourcing and delivering cutting-edge solutions positions it as a reliable partner for academic and pharmaceutical R&D. The company's lack of disclosed funding or revenue data suggests it is early-stage or privately funded, relying on product sales and partnerships for growth. As the demand for advanced research tools continues to rise, Mayflower has the potential to capture market share through differentiated offerings and strong customer support.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation gene editing kit70% success
• H2 2026Strategic partnership with a top-20 pharma company50% success
• Q4 2026Expansion of product portfolio into automated cell culture systems60% success